Drug Profile
Research programme: SVec viral vector therapeutics - Amarna Therapeutics
Latest Information Update: 20 Oct 2020
Price :
$50
*
At a glance
- Originator Amarna Therapeutics
- Class Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Multiple sclerosis
- Discontinued Age-related macular degeneration; Breast cancer
Most Recent Events
- 29 Sep 2020 Amarna Therapeutics and Progreso y Salud Foundation agree to co-promote and co-develop SVec™ viral vector therapeutics for Multiple sclerosis
- 25 Sep 2020 SVec viral vector therapeutics are still in early research trials for Multiple sclerosis in the Netherlands (unspecified route) prior to September 2020
- 21 Aug 2019 Discontinued for Age-related macular degeneration in Netherlands (unspecified route)